Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIVOT-12 adjuvant bempegaldesleukin plus nivolumab versus nivolumab in resected high-risk melanoma
NL-OMON55317Phase 3Completed
- Sponsor
- Nektar Therapeutics
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in cutaneous melanoma (CM) comparing Bempegaldesleukin + nivolumab with Nivolumab (2 arms). Primary endpoint: Recurrence-free survival by blinded independent central review. Started Feb 2021; status: completed.
02
Drugs
bempegaldesleukinnivolumab
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NL-OMON55317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55317.